Veracyte, Inc. VCYT
Regular-session close
After hours · Nov 16, 5:42 PM ET
- YTD
- -42.97%
- 1 year
- -38.98%
- Market cap
- 1.94B
- Revenue (ttm)
- 581.78M
- Profit margin
- 21.80%
- EPS (ttm)
- 1.54
- Shares out
- 80.70M
- P/E ratio
- 15.59
- Forward P/E
- 15.33
- YTD return
- -42.97%
- 1-year return
- -38.98%
- 50-day average
- 42.16
- Volume
- 2.19M
- Avg volume
- 1.79M
- Open
- 23.97
- Previous close
- 24.33
- Day's range
- 23.27 – 24.57
- 52-week range
- 21.91 – 60.91
- Beta
- 1.96
- Analysts
- Buy
- Price target
- 44.60 (+85.8%)
- Earnings date
- Feb 24, 2027
5D -0.39 (-1.58%)
Key statistics
- 200-day average
- 42.38
- Enterprise value
- 1.63B
- Price / sales
- 3.33
- Price / book
- 1.35
- Revenue growth
- 15.10%
- Free cash flow
- 110.92M
- Total cash
- 370.53M
- Total debt
- 40.74M
- Return on equity
- 9.43%
- Short % of float
- 13.99%
Fundamental scorecard
17 of 25 checks passed on VCYT’s reported financials
17of 25 checks passed
- Value 4 of 5
- Growth 5 of 5
- Profitability 3 of 5
- Financial health 5 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: buy
- Target (low)
- 30.00
- Target (mean)
- 44.60
- Target (high)
- 65.00
- Strong buy2
- Buy7
- Hold3
- Sell0
- Strong sell0
Next earnings
Feb 24, 2027
Expected Feb 24, 2027. Consensus EPS estimate 0.38299.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 24, 2027 | Dec 30, 2026 | 0.40 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | 0.4102 | 0.51 | +0.10 | +24.33% |
| Jul 30, 2026 | Jun 30, 2026 | 0.4103 | 0.54 | +0.13 | +31.61% |
| May 5, 2026 | Mar 31, 2026 | 0.34 | 0.52 | +0.18 | +52.94% |
| Feb 25, 2026 | Dec 31, 2025 | 0.4083 | 0.53 | +0.12 | +29.81% |
| Nov 4, 2025 | Sep 30, 2025 | 0.32 | 0.51 | +0.19 | +59.38% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 11, 2026 | Stephens & Co. | main | Overweight | Overweight |
| Nov 10, 2026 | Piper Sandler | main | Overweight | Overweight |
| Nov 10, 2026 | Freedom Capital Markets | main | Buy | Buy |
| Nov 9, 2026 | UBS | main | Buy | Buy |
| Nov 5, 2026 | Leerink Partners | down | Outperform | Market Perform |
| Nov 5, 2026 | Needham | main | Buy | Buy |
About Veracyte, Inc.
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- veracyte.com
News
Veracyte (VCYT) Securities Investigation Notice - Levi & Korsinsky
Veracyte: Solid Profits, Slowing Tests, And A Stock In Limbo Stephens & Co. Maintains Overweight on Veracyte, Lowers Price Target to $40
Veracyte, Inc. (VCYT) Presents at 2026 UBS Global Healthcare Conference Transcript
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Veracyte (VCYT) Piper Sandler Maintains Overweight on Veracyte, Lowers Price Target to $30
Freedom Capital Markets Maintains Buy on Veracyte, Lowers Price Target to $40
VCYT Investors Have Opportunity to Join Veracyte, Inc. Fraud Investigation with SBS Law UBS Maintains Buy on Veracyte, Lowers Price Target to $35
12 Health Care Stocks Moving In Thursday's Intraday Session
Your note
Sign in to keep a note on VCYT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARR ELIAV | Director | Stock Award(Grant) | Jun 10, 2026 | 56,461 |
| BHANJI MUNA | Director | Sale | Oct 18, 2026 | 40,854 |
| CHAMBERS REBECCA | Chief Financial Officer | Sale | Sep 3, 2026 | 166,025 |
| EPSTEIN ROBERT S | Director | Stock Award(Grant) | Jun 10, 2026 | 57,718 |
| FEBBO PHILLIP G | Officer | Sale | Sep 3, 2026 | 133,048 |
| HAAS KEVIN RICHARD | Officer | Stock Award(Grant) | Apr 9, 2026 | 44,221 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 17.21% | 13,887,188 | 333.43M | Sep 29, 2026 |
| FMR, LLC | 8.07% | 6,512,651 | 156.37M | Sep 29, 2026 |
| State Street Corporation | 6.86% | 5,532,737 | 132.84M | Sep 29, 2026 |
| Vanguard Portfolio Management LLC | 5.99% | 4,836,979 | 116.14M | Sep 29, 2026 |
| Vanguard Capital Management LLC | 4.46% | 3,600,336 | 86.44M | Sep 29, 2026 |
| ARK Investment Management, LLC | 3.67% | 2,964,650 | 71.18M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.93% | 4,787,107 | 114.94M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.14% | 2,532,110 | 60.80M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.89% | 2,332,081 | 55.99M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.59% | 2,092,968 | 50.25M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.27% | 1,830,642 | 43.95M | Jun 29, 2026 |
| ARK ETF Trust-ARK Genomic Revolution ETF | 1.99% | 1,609,811 | 38.65M | Oct 30, 2026 |
